Fortress Biotech, Inc. (FBIO)
2.11
-0.02
(-1.17%)
USD |
NASDAQ |
Oct 12, 14:23
Fortress Biotech Cash from Investing (Quarterly) : -0.079M for June 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.079M |
| March 31, 2026 | 0.00 |
| December 31, 2025 | 0.00 |
| September 30, 2025 | 2.87M |
| June 30, 2025 | 6.086M |
| March 31, 2025 | 1.165M |
| December 31, 2024 | -15.00M |
| September 30, 2024 | 0.00 |
| June 30, 2024 | 0.00 |
| March 31, 2024 | 0.00 |
| December 31, 2023 | -0.063M |
| September 30, 2023 | 4.999M |
| June 30, 2023 | -2.039M |
| March 31, 2023 | -5.00M |
| December 31, 2022 | -0.391M |
| September 30, 2022 | -0.893M |
| June 30, 2022 | -0.307M |
| March 31, 2022 | -21.34M |
| December 31, 2021 | 53.35M |
| September 30, 2021 | -7.541M |
| June 30, 2021 | -4.84M |
| March 31, 2021 | -0.458M |
| December 31, 2020 | -1.567M |
| September 30, 2020 | -2.758M |
| June 30, 2020 | -1.063M |
| Date | Value |
|---|---|
| March 31, 2020 | -1.776M |
| December 31, 2019 | 0.31M |
| September 30, 2019 | -3.75M |
| June 30, 2019 | -0.611M |
| March 31, 2019 | 24.15M |
| December 31, 2018 | |
| September 30, 2018 | 9.331M |
| June 30, 2018 | -2.189M |
| March 31, 2018 | -1.84M |
| December 31, 2017 | 4.372M |
| September 30, 2017 | -24.84M |
| June 30, 2017 | -20.22M |
| March 31, 2017 | -0.942M |
| December 31, 2016 | -1.305M |
| September 30, 2016 | 2.166M |
| June 30, 2016 | -4.218M |
| March 31, 2016 | -2.703M |
| December 31, 2015 | 29.30M |
| September 30, 2015 | -20.00M |
| June 30, 2015 | -0.049M |
| March 31, 2015 | -1.358M |
| December 31, 2014 | -22.68M |
| September 30, 2014 | -0.05M |
| June 30, 2014 | -0.295M |
| March 31, 2014 | -0.25M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Inovio Pharmaceuticals, Inc. | 6.147M |
| Kura Oncology, Inc. | 92.21M |
| Spero Therapeutics, Inc. | 0.00 |
| ACADIA Pharmaceuticals, Inc. | -8.529M |
| Alnylam Pharmaceuticals, Inc. | -363.46M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -59.28M |
| Cash from Financing (Quarterly) | 0.091M |
| Free Cash Flow | 120.28M |
| Free Cash Flow Per Share (Quarterly) | -1.867 |
| Free Cash Flow to Equity (Quarterly) | -59.04M |
| Free Cash Flow to Firm (Quarterly) | -58.39M |
| Free Cash Flow Yield | 169.3% |